Skip to main content
OLYMPUS CORPORATION logo

OLYMPUS CORPORATION — Investor Relations & Filings

Ticker · 7733 ISIN · JP3201200007 LEI · 5299000Y52IFDI1I2A21 T Manufacturing
Open in API
Filings indexed 105 across all filing types
Latest filing 2026-06-05 Transaction in Own Shar…
Country JP Japan
Listing T 7733

About OLYMPUS CORPORATION

https://www.olympus-global.com/

Olympus Corporation is a global medical technology (medtech) company focused on making people's lives healthier, safer, and more fulfilling. The company develops, manufactures, and commercializes innovative solutions for the medical and healthcare sectors, specializing in early detection, diagnosis, and minimally invasive treatment. Its core product portfolio includes medical endoscopes, endotherapy devices, and therapeutic energy devices. These technologies are applied across various medical specialties such as gastroenterology, urology, gynecology, and general surgery. Leveraging its expertise in optical and digital precision technology, Olympus provides comprehensive solutions that also encompass advanced video imaging systems and system integration services for healthcare facilities.

Recent filings

Filing Released Lang Actions
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 91% confidence The document is a detailed statutory report under Japan’s Financial Instruments and Exchange Act (Article 24-6) disclosing the status of treasury stock repurchases (dates, quantities, amounts, progress, and holdings). This is precisely a company buying back its own shares, matching the definition of Transaction in Own Shares (POS).
2026-06-05 Japanese
(Progress of disclosure matters) Notice Regarding Completion of Acquisition of BioProtect Ltd.
M&A Activity Classification · 87% confidence The document is a press release/timely disclosure announcing the completion of an acquisition (BioProtect Ltd.) by Olympus Corporation, including deal terms and shareholding details. This falls squarely under M&A activity announcements rather than financial results or regulatory filings. Therefore, it should be classified as M&A Activity (TAR).
2026-06-02 English
（開示事項の経過）BioProtect Ltd.の株式の取得（子会社化）の完了に関するお知らせ
M&A Activity Classification · 92% confidence The document is a Japanese securities disclosure announcing the completion of the acquisition of all shares of BioProtect Ltd. (making it a wholly-owned subsidiary). It details the transaction structure, share counts, purchase price and post-transaction holding, clearly relating to an M&A transaction. This falls under M&A Activity (TAR).
2026-06-02 Japanese
BioProtect Ltd.の株式の取得（子会社化）に関するお知らせ
M&A Activity Classification · 90% confidence The document is a Japanese IR announcement from Olympus detailing its decision to acquire 100% of BioProtect Ltd.’s shares and make it a wholly owned subsidiary. It includes the purpose of the acquisition, target company details, number of shares acquired, acquisition price, dates, and pro forma financial outlook. This is an M&A transaction announcement, which best fits the “M&A Activity” category (Code: TAR) rather than a financing update or regulatory fall-back.
2026-05-26 Japanese
発行登録追補書類（株券､社債券等）
Share Issue/Capital Change Classification · 95% confidence The document is an issuance registration supplementary filing (発行登録追補書類) submitted to the Kanto Local Finance Bureau, detailing the terms, conditions, amounts, allotment methods, and related information for an issuance of shares (including disposal of treasury shares under RSU/PSU programs). It is not an earnings release, annual report, proxy statement, or mere announcement—it is the formal prospectus-like registration for a share issuance. According to the category definitions, this falls under Share Issue/Capital Change (SHA).
2026-05-14 Japanese
自己株式立会外買付取引（ToSTNeT-3）による自己株式の買付けに関するお知らせ
Transaction in Own Shares Classification · 95% confidence The document is a notice from Olympus Corporation detailing the Board of Directors’ resolution and specific method for acquiring treasury shares (share buyback) under the Companies Act and the company’s Articles. It includes the repurchase mechanism (ToSTNeT-3), maximum number of shares, total purchase amount, and timing. This clearly falls under “Transaction in Own Shares” (share repurchase) rather than a new share issuance or other capital change.
2026-05-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.